Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting Watch Here

EXCLUSIVE: Ascent CEO Colin Hutchinson with latest on review and permitting


Hemogenyx Share Price (HEMO)



Share Price Information for Hemogenyx (HEMO)


Share Price: 2.70Bid: 2.50Ask: 2.90Change: 0.00 (0.00%)No Movement on Hemogenyx
Spread: 0.40Spread as %: 16.00%Open: 2.65High: 2.70Low: 2.65Yesterday’s Close: 2.70

Hemogenyx Pharmaceuticals Plc Ord Gbp0.01

Hemogenyx is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
2.70
Share Price SpacerBid
2.50
Share Price SpacerAsk
2.90
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
453,965
Share Price SpacerOpen
2.65
Share Price SpacerHigh
2.70
Share Price SpacerLow
2.65
Share Price SpacerClose
2.70
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 360.05m £9.72m 30,000

52 Week High 6.75 52 Week High Date 26-FEB-2018
52 Week Low 2.00 52 Week Low Date 22-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
4 0 353,965 -3.000 -0.90 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

15-Aug-18
08:34:25
2.77
50,000
Buy* 
2.50
2.80
1,385
Trade Type:
Ordinary

15-Aug-18
08:22:57
2.79
200,000
Buy* 
2.50
2.80
5,580
Trade Type:
Ordinary

15-Aug-18
08:15:19
2.66
103,965
Buy* 
2.50
2.80
2,765
Trade Type:
Ordinary




View more Hemogenyx trades >>

Directors Deals for Hemogenyx (HEMO)
Trade DateActionNotifierPriceCurrencyAmountHolding
05-Feb-18Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Vladislav Sandler Ph.D. held the position of CEO at Hemogenyx Pharmaceuticals at the time of this trade.
 Vladislav Sandler Ph.D.
2.37GBX26,80040478010
06-Oct-17Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Adrian Beeston held the position of Non-Executive Director at Hemogenyx Pharmaceuticals at the time of this trade.
 Adrian Beeston
3.1GBX10,0005424286
06-Oct-17Buy
Trade Notifier Information for Hemogenyx Pharmaceuticals
Peter Redmond held the position of Non-Executive Director at Hemogenyx Pharmaceuticals at the time of this trade.
 Peter Redmond
3.14GBX155,0005040714
View more Hemogenyx directors dealings >>


Shukan
Posts: 2,004
Opinion:No Opinion
Price:2.60
RE: Looking dire
Fri 19:53
We know Bio Techs are slow - might have something to say soon
SteJSteJ
Posts: 7
Opinion:No Opinion
Price:2.60
RE: Looking dire
Fri 11:32
It is a share that will move on news until some results come out. No news will mean it drifts downwards as people look for other opportunities.

Whilst I would love to hear news to keep the share price on the up (or at least on the level) if they don't have anything to tell us (good or bad) then its better they focus their energies on the research.

Ultimately, the news will drop one day and the share price will move. Hopefully upwards and by a lot!
ontarget
Posts: 1,718
Premium Chat Member
Opinion:No Opinion
Price:2.55
Looking dire
Fri 09:51
'ere as bored holders dribble out in a paper thin market.
If the company can't muster any news then some director buying wouldn't go amiss perhaps? Directors with options at 3.5p can now buy at just above 2.5p in the market.
FeverClucker
Posts: 606
Opinion:No Opinion
Price:2.75
Lots of buys
9 Aug '18
....showing as sells
YTSS
Posts: 479
Opinion:No Opinion
Price:2.75
RE: 18 months
1 Aug '18
Oxford uni became involved with the expansion.of stem cells in vitro etc. Is this what you are referring to. Main limitation currently with the use if e.g cord cells in transplantation is the small no.s of cells harvested. Upside is reduction in graft v host disease ie rejection
The extraction of stem cells from patients own liver has the same limitations in cells harvested.
Hopfully will be addressed with oxfords help
What connference is Mark Feldman presenting at in Oxford as not far from me
View more share chat for Hemogenyx (HEMO) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.